Tuesday 4 September 2012

Atox Bio to seek funds by year-end for more trials

TEL AVIV (Reuters) - Israeli biotechnology firm Atox Bio, developing a drug it hopes can treat severe infections such as those caused by flesh-eating bacteria and deadly viruses, expects to ask investors for more money this year to fund extended phase II trials. Chief executive Dan Teleman also told Reuters on Tuesday he expected to have results of current clinical trials by year-end. Atox Bio has been conducting Phase II clinical trials at seven medical centers in the United States where 40 patients with flesh-eating bacteria, or necrotizing soft tissue infections (NSTI), have been treated. ... via Health News Headlines - Yahoo! News Read More Here..

No comments:

Post a Comment